Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
PK Coyle, MS Freedman, BA Cohen… - Annals of Clinical …, 2024 - Wiley Online Library
Abstract Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod,
ponesimod, and siponimod) are approved by the US Food and Drug Administration for the …
ponesimod, and siponimod) are approved by the US Food and Drug Administration for the …
Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies
A Abdelrahman, E Alvarez - Neurologic Clinics, 2024 - neurologic.theclinics.com
We live in an exciting time for the treatment of patients with multiple sclerosis (MS). We now
possess a vast armamentarium of effective therapies, which offer neuroprotection by …
possess a vast armamentarium of effective therapies, which offer neuroprotection by …
[HTML][HTML] Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
CEA Corsten, SA Huygens, MM Versteegh… - Multiple Sclerosis and …, 2023 - Elsevier
Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently
available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (ie …
available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (ie …
SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
Objective To investigate the serologic response, predictors of response, and clinical
outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) …
outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) …
Immune response to initial and booster SARS-CoV-2 mRNA vaccination in patients treated with siponimod—final analysis of a nonrandomized controlled clinical trial …
T Ziemssen, M Groth, VE Winkelmann, T Bopp - Vaccines, 2023 - mdpi.com
Background: Evidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is
rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 …
rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 …
[HTML][HTML] T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
AS Wolf, A Ravussin, M König, MH Øverås, G Solum… - JCI insight, 2023 - ncbi.nlm.nih.gov
Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying
therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic …
therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic …
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
GK Al Rahbani, C Woopen, M Dunsche, U Proschmann… - Vaccines, 2024 - mdpi.com
Disease-modifying therapies (DMTs) impact the cellular immune response to severe acute
respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with multiple …
respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with multiple …
The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases
SS Kar, SR Gharai, SK Sahu… - Current Topics in …, 2024 - ingentaconnect.com
Sphingosine 1-phosphate (S1P) is extensively researched as a lysophospholipid and is
crucial in various physiological and pathological processes. It achieves this via signalling …
crucial in various physiological and pathological processes. It achieves this via signalling …
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
CEA Corsten, SA Huygens, MM Versteegh… - medRxiv, 2022 - medrxiv.org
Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently
available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (ie …
available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (ie …
Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug …
C Schmidt, A Stallmach, A Sturm… - Zeitschrift für …, 2024 - thieme-connect.com
In Deutschland haben sich nach Angaben des RKI seit Beginn der SARS-CoV-2-Pandemie
ca. 38, 5 Mio. Menschen mit dem Virus infiziert, über 176 000 Meschen sind an COVID-19 …
ca. 38, 5 Mio. Menschen mit dem Virus infiziert, über 176 000 Meschen sind an COVID-19 …